The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Open accessAbstract
Objective: To compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with atrial fibrillation. Design: Systematic review, network meta-analysis, and cost effectiveness analysis. Data sources: Medline, PreMedline, Embase, and The Cochrane Library. Eligibility criteria for selecting studies: Published randomised trials evaluating the use of a DOAC, vitamin K antagonist, or antiplatelet drug for prevention of stroke in patients with atrial fibrillation. Results: 23 randomised trials involving 94 656 patients were analysed: 13 compared a DOAC with warfarin dosed to achieve a target INR of 2.0-3.0. Apixaban 5 mg twice daily (odds ratio 0.79, 95% confidence interval 0.66 to 0.94), dabigatran 150 mg twice daily (0.65, 0.52 to 0.81), edoxaban 60 mg once daily (0.86, 0.74 to 1.01), and rivaroxaban 20 mg once daily (0.88, 0.74 to 1.03) reduced the risk of stroke or systemic embolism compared with warfarin. The risk of stroke or systemic embolism was higher with edoxaban 60 mg once daily (1.33, 1.02 to 1.75) and rivaroxaban 20 mg once daily (1.35, 1.03 to 1.78) than with dabigatran 150 mg twice daily. The risk of all-cause mortality was lower with all DOACs than with warfarin. Apixaban 5 mg twice daily (0.71, 0.61 to 0.81), dabigatran 110 mg twice daily (0.80, 0.69 to 0.93), edoxaban 30 mg once daily (0.46, 0.40 to 0.54), and edoxaban 60 mg once daily (0.78, 0.69 to 0.90) reduced the risk of major bleeding compared with warfarin. The risk of major bleeding was higher with dabigatran 150 mg twice daily than apixaban 5 mg twice daily (1.33, 1.09 to 1.62), rivaroxaban 20 mg twice daily than apixaban 5 mg twice daily (1.45, 1.19 to 1.78), and rivaroxaban 20 mg twice daily than edoxaban 60 mg once daily (1.31, 1.07 to 1.59). The risk of intracranial bleeding was substantially lower for most DOACs compared with warfarin, whereas the risk of gastrointestinal bleeding was higher with some DOACs than warfarin. Apixaban 5 mg twice daily was ranked the highest for most outcomes, and was cost effective compared with warfarin. Conclusions: The network meta-analysis informs the choice of DOACs for prevention of stroke in patients with atrial fibrillation. Several DOACs are of net benefit compared with warfarin. A trial directly comparing DOACs would overcome the need for indirect comparisons to be made through network meta-analysis. Systematic review registration: PROSPERO CRD 42013005324.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Self-citationCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Self-citationDabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00583-9 · Cited by 2,033
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,638
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Self-citationRivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation: – The J-ROCKET AF Study –
Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S.-I., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0454 · Cited by 641
Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.042 · Cited by 480
Lopes, R. D., Alexander, J. H., Al-Khatib, S. M., Ansell, J., Diaz, R., Easton, J. D., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.07.035 · Cited by 457
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Connolly, S., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., Kastrissios, H., Jin, J., Kunitada, S., & Weitz, J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0066 · Cited by 341
Healey, J. S., Oldgren, J., Ezekowitz, M., Zhu, J., Pais, P., Wang, J., Commerford, P., Jansky, P., Avezum, A., Sigamani, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30968-0 · Cited by 285
Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care
Lane, D. A., Skjøth, F., Lip, G. Y. H., Larsen, T. B., & Kotecha, D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005155 · Cited by 283
Lee, S., Shafe, A. C. E., & Cowie, M. R. (2011) · BMJ Open · doi:10.1136/bmjopen-2011-000269 · Cited by 224
Lip, G. Y. H., Diener, H.-C., Brueckmann, M., van Ryn, J., Clemens, A., & Huisman, M. V. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0718 · Cited by 218
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Self-citationEikelboom, J. W., O'Donnell, M., Yusuf, S., Diaz, R., Flaker, G., Hart, R., Hohnloser, S., Joyner, C., Lawrence, J., Pais, P., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.08.026 · Cited by 163
Coyle, D., Coyle, K., Cameron, C. G., Lee, K. S., Kelly, S., Steiner, S., & Wells, G. A. (2013) · Value in Health · doi:10.1016/j.jval.2013.01.009 · Cited by 154
Ogawa, S., Shinohara, Y., & Kanmuri, K. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1183 · Cited by 146
Verheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Kansal, A. R., Sorensen, S. V., Gani, R., Robinson, P. J., Pan, F., Plumb, J. M., & Cowie, M. (2012) · Heart · doi:10.1136/heartjnl-2011-300646 · Cited by 125
Connolly, S. J., Eikelboom, J. W., Dorian, P., Hohnloser, S. H., Gretler, D. D., Sinha, U., & Ezekowitz, M. D. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht039 · Cited by 124
Rasmussen, L. H., Larsen, T. B., Graungaard, T., Skjøth, F., & Lip, G. Y. H. (2012) · BMJ · doi:10.1136/bmj.e7097 · Cited by 122
Yamashita, T., Koretsune, Y., Yasaka, M., Inoue, H., Kawai, Y., Yamaguchi, T., Uchiyama, S., Matsumoto, M., & Ogawa, S. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1140 · Cited by 113
Jeon, H., Lien, L., Lai, W.-T., Tse, H., Chung, W.-S., Lee, T.-H., Chen, S.-A., & Chung, N. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-07-0451 · Cited by 107
Mangtani, P., Nguipdop‐Djomo, P., Keogh, R. H., Trinder, L., Smith, P. G., Fine, P., Sterne, J. A. C., Abubakar, I. I., Vynnycky, E., Watson, J. M., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21390 · Cited by 93
Self-citationDogliotti, A., Paolasso, E., & Giugliano, R. P. (2013) · Heart · doi:10.1136/heartjnl-2013-304347 · Cited by 70
Cope, S. F., Clemens, A., Hammès, F., Noack, H., & Jansen, J. P. (2015) · Value in Health · doi:10.1016/j.jval.2014.10.012 · Cited by 53
Lin, L., Lim, W. S., Zhou, H. J., Khoo, A. L., Tan, K. T., Chew, A. P., Foo, D. C. G., Chin, J. J., & Lim, B. P. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.09.008 · Cited by 52
Hu, D., Zhang, H.-P., Sun, Y., & Jiang, L. (2006) · PubMed · Cited by 47
Assiri, A. M., Al-Majzoub, O., Kanaan, A. O., Donovan, J. L., & Silva, M. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.05.011 · Cited by 41
Potpara, T., & Lip, G. Y. H. (2017) · JAMA · doi:10.1001/jama.2017.1152 · Cited by 41
Cited by
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,028
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
Action Plan for Stroke in Europe 2018–2030
Norrving, B., Barrick, J., Davalos, A., Dichgans, M., Cordonnier, C., Guekht, A., Kutluk, K., Mikulik, R., Wardlaw, J., Richard, E., et al. (2018) · European Stroke Journal · doi:10.1177/2396987318808719 · Cited by 600
Genetic drug target validation using Mendelian randomisation
Schmidt, A. F., Finan, C., Gordillo-Marañón, M., Asselbergs, F. W., Freitag, D. F., Patel, R. S., Tyl, B., Chopade, S., Faraway, R., Zwierzyna, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16969-0 · Cited by 567
Self-citation
Metadata
- Authors
- López-López, J. A., Sterne, J. A. C., Thom, H. H. Z., Higgins, J. P. T., Hingorani, A. D., Okoli, G. N., Davies, P. A., Bodalia, P. N., Bryden, P. A., Welton, N. J., Hollingworth, W., Caldwell, D. M., Savović, J., Dias, S., Salisbury, C., Eaton, D., Stephens-Boal, A., & Sofat, R.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2017-11-28
- Volume
- 359
- Pages
- j5058
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2769275060
- Cited by
- 547
- References
- 36
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.